צמיחת מכירות ב-12 חודשים נגררים: Beam Tx (BEAM)

Beam Therapeutics Inc. (BEAM) is establishing efficient DNA material logistics through its laboratory network while maintaining high margins. The LTM annual sales growth rate illustrates the resilience of this model, where the value of 163.40 reflects the metric's balance. Share prices depend on BEAM-101 trials and lipid technologies, while current liquidity reserves and R&D expenses are already priced into the market value of the stocks.
Beam Therapeutics Inc (BEAM) - פילוחי מדדים ודוחות פיננסיים

Beam Therapeutics Inc. (BEAM) revenues depend on the successful market launch of innovative precision DNA base editing drugs. The calculation algorithm aggregates revenue over the last twelve months, neutralizing time gaps between quarterly reports. This metric assesses the fundamental efficiency of therapy commercialization and the speed of business scaling. By analyzing the TTM revenue growth rate compared to the previous year, an investor can evaluate the sustainability of the company's expansion.